[Edaily Reporter Park Jung-Soo ] Pangen Biotech Inc.(222110)announced on the 22nd that it has been awarded a research contract worth 2.74545 billion won from the National Institute of Health under the Korea Disease Control and Prevention Agency (KDCA) for the “Optimization and Evaluation of a Non-clinical Sample Production System for Antibodies to Treat Severe Fever with Thrombocytopenia Syndrome (SFTS).” The contract amount represents 20.46% of last year’s revenue, and the contract period runs through December 31, 2028.
Disclosure Plus
Pangen Biotech Inc. Wins 2.7 Billion Won Research Contract from the National Institute of Health
Park Jung-Soo
2026-06-22 13:55:45
Economy
Corporation
IT·Science
Economy
[VC's Pick] Deep Tech on the Rise: From Robotics to Quantum Computing and SMRs
This week (October 12–16), startups in various fields—including robotics, quantum computing, and small modular reactor (SMR) engineering—secured investments from venture capital (VC) firms and acceler…
Corporation
"Even with Lower Farm-Gate Prices, Why Is a Tray of Eggs Still 7,000 Won?"…The Reason They Remain Expensive [Why This Price]
“Why is it priced this way?” We’ll answer those questions about prices that have crossed your mind at least once as you absentmindedly reached for your wallet. From department stores to convenience st…
IT·Science
“Wasn’t it a disease that disappeared in the Middle Ages?”… What Is the Black Death Cure That Has Emerged in Russia? [Pharmaceutical Insights]
Although the plague is often thought of as a disease that disappeared along with the Middle Ages, it still circulates among wild rodents and fleas today. According to the World Health Organization (WH…
